Complete report is available @ . br br The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2, according to a new report from research and consulting firm. br br The company’s latest report* states that out of the eight major markets — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4 and expand its market share from 55 to 61.7 during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1 and 0.5, respectively. br br According to Researcher, the growth in HBV vaccine sales will result from the launch of Dynavax Technologies’ Heplisav and Sanofi Pasteur MSD’s Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively.